Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR–ABL kinase inhibitors Structure–activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitors Discovery of novel Bcr–Abl inhibitors targeting myristoyl pocket and ATP site Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors Design, synthesis, and biological activity of 4-(imidazo[1,2- b ]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant